Siggelkow, Heide

[["dc.bibliographiccitation.firstpage","223"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Oezerden, M. M."],["dc.contributor.author","Braune, I."],["dc.contributor.author","Kluge, G."],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T09:14:40Z"],["dc.date.available","2018-11-07T09:14:40Z"],["dc.date.issued","2012"],["dc.description.abstract","The prevalence of cervical lymphadenopathy in autoimmune thyroiditis (AIT) patients is actually unknown. The aim of the study was the detailed retrospective evaluation of 6 index-patients with lymphadenopathy in Robbins level VI and a prospective study with high resolution ultrasound of lymphadenopathy in All patients compared with controls in all compartments of the neck, accessible to sonographic evaluation. Patients, methods: The retrospective study comprises six patients with AIT, evaluated for enlarged Robbins level VI-LN. We report the findings of fine-needle aspiration Cytology, clonal analysis, histology, and serological testing. The prospective study evaluated the prevalence of lymphadenopathy in 49 consecutive patients with AIT (group 1) and 49 consecutive patients with normal thyroids or nontoxic goiter (group2). Results: In the retrospective study, cytology of paratracheal LN revealed reactive lymphoid hyperplasia in 5/6 of the cases and a centroblastic lymphoma in one patient. The presence of monoclonal lymphatic cells was excluded in 5/6 patients and proven in 1/6 patients. Actual viral-infections were ruled out. In the prospective study All-patients showed significantly more enlarged LN in Robbins level II-IV and VI compared to controls. We found no correlation between lymphadenopathy, age, thyroid volume and nodularity, or autoantibody levels. During follow-up in 34 group 1-patients, lymphadenopathy remained stable in 28 patients, and decreased in 6 patients. Conclusion: Lymphadenopathy in Robbins level II-IV and VI is common in AIT-patients and most probably related to the autoimmune process."],["dc.identifier.doi","10.3413/Nukmed-0484-12-03"],["dc.identifier.isi","000312613800004"],["dc.identifier.pmid","23042429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27472"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Patients with autoimmune thyroiditis Prevalence of benign lymphadenopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Bone and Mineral Research"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Kluever, A."],["dc.contributor.author","Ponce, M. L."],["dc.contributor.author","Hufner, M."],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2018-11-07T10:45:16Z"],["dc.date.available","2018-11-07T10:45:16Z"],["dc.date.issued","2004"],["dc.format.extent","S270"],["dc.identifier.isi","000224326801438"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47469"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Bone & Mineral Res"],["dc.publisher.place","Washington"],["dc.relation.conference","26th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research"],["dc.relation.eventlocation","Seattle, WA"],["dc.relation.issn","0884-0431"],["dc.title","Expression of the Human Urea Transporter HUT11 in comparison to the adipogenic marker aP2 in subpopulations of primary human osteoblasts"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","JBMR Plus"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Wilde, Deborah"],["dc.contributor.author","Wilken, Lara"],["dc.contributor.author","Stamm, Bettina"],["dc.contributor.author","Blaschke, Martina"],["dc.contributor.author","Heppner, Christina"],["dc.contributor.author","Chavanon, Mira‐Lynn"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Herrmann‐Lingen, Christoph"],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2021-06-01T10:50:47Z"],["dc.date.available","2021-06-01T10:50:47Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/jbm4.10245"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17136"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86788"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2473-4039"],["dc.relation.issn","2473-4039"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The HPQ—Development and First Administration of a Questionnaire for Hypoparathyroid Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","214"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cells Tissues Organs"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","170"],["dc.contributor.author","Frosch, Karl-Heinz"],["dc.contributor.author","Barvencik, F."],["dc.contributor.author","Lohmann, Christoph H."],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Breme, J."],["dc.contributor.author","Dresing, Klaus"],["dc.contributor.author","Sturmer, K. M."],["dc.date.accessioned","2018-11-07T10:32:53Z"],["dc.date.available","2018-11-07T10:32:53Z"],["dc.date.issued","2002"],["dc.description.abstract","The goal of this study was to characterize growth, mineralization and bone formation of osteoblast-like cells in titanium pore channels of defined diameter. Titanium implants with continuous drill channels of diameters of 300, 400, 500, 600 and 1,000 mum were inserted into human osteoblast-like cell cultures. The ingrowth of the cells into the drill channels was investigated by transmitted-light microscopy and scanning electron microscopy. Immunofluorescence and histological analysis of 15-channel sections of each diameter were used to investigate the growth behavior and the matrix protein patterns. Mineralization was evidenced by Alizarin red staining and high-resolution microradiography. The ingrowth of human osteoblast-like cells in the drill channels occurred in a sequence of four characteristic stages. In stage 1, osteoblast precursor cells adhered to the wall of the channel and migrated three-dimensionally into the channel by forming foot-like protoplasmic processes. For all 15 sample drill channels that were investigated, the cell ingrowth over 20 days amounted on average to 793 mum (+/- 179) into 600-mum-diameter channels, where they migrated significantly faster than in all the other channels. In stage 2, approximately on day 5-7, the osteoblast-like cells began to anchor on the substrate wall by matrix proteins and to build up a dense network of matrix proteins in the drill channel. The mineralization of the extracellular matrix, while depending on cell stimulation, was initiated in stage 3, on average after 4 weeks. In drill channels of a diameter of 1,000 mum the cell growth was incomplete and no mineralization was found by radiological assessment. Starting in week 6, in the drill channels of diameters ranging from 300 to 600 mum, the network of extracellular matrix proteins and osteoblast-like cells began to form an osteon-like structure. Neither the highly developed migration behavior of osteoblastic cells nor the reorganization from a fiber-like matrix to a lamellar structure have so far been described for cell cultures."],["dc.identifier.doi","10.1159/000047925"],["dc.identifier.isi","000174840400002"],["dc.identifier.pmid","11919409"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44464"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1422-6405"],["dc.title","Migration, matrix production and lamellar bone formation of human osteoblast-like cells in porous titanium implants"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","28"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cellular Biochemistry"],["dc.bibliographiccitation.lastpage","40"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Pannem, Rajeswararao"],["dc.contributor.author","Braulke, Thomas"],["dc.contributor.author","Scharf, Jens-Gerd"],["dc.contributor.author","Kuebler, Bernd"],["dc.date.accessioned","2018-11-07T10:59:07Z"],["dc.date.available","2018-11-07T10:59:07Z"],["dc.date.issued","2007"],["dc.description.abstract","The insulin-like growth factors I and II (IGF-I, IGF-II), their receptors, and high affinity binding proteins (IGFBPs) represent a family of cellular modulators that play essential roles in the development and differentiation of cells and tissues including the skeleton. Recently, the human osteosarcoma cell line HOS 58 cells were used as an in vitro model of osteoblast differentiation characterized by (i) a rapid proliferation rate in low-density cells that decreased continuously with time of culture and (ii) an increasing secretion of matrix proteins during their in vitro differentiation. In the present paper, HOS 58 cells with low cell density at early time points of the in vitro differentiation (i) displayed a low expression of IGF-I and -II; (ii) synthesized low levels of IGFBP-2, -3, -4, and -5, but (iii) showed high expression levels of both the type I and II IGF receptors. During the in vitro differentiation of HOS 58 cells, IGF-I and -II expressions increased continuously in parallel with an upregulation of IGFBP-2, -3, -4, and -5 whereas the IGF-I receptor and lGF-II/M6P receptor mRNA were downregulated. in conclusion, the high proliferative activity in low cell density HOS 58 cells was associated with high mRNA levels of the IGF-IR, but low concentrations of IGFBP-2. The rate of proliferation of HOS 58 cells continuously decreased during cultivation in parallel with a decline in IGF-IR expression, but increase of mitoinhibitory IGFBP-2. These data are indicative for a role of the IGF axis during the in vitro differentiation of HOS 58 cells. J. Cell. Biochem. 102: 28-40, 2007. (C) 2007 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/jcb.21274"],["dc.identifier.isi","000249263100003"],["dc.identifier.pmid","17372931"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50624"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0730-2312"],["dc.title","Alteration of the insulin-like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Experimental and Clinical Endocrinology & Diabetes"],["dc.contributor.author","Witzel, Judith Charlotte"],["dc.contributor.author","Giessel, Anna"],["dc.contributor.author","Heppner, Christina"],["dc.contributor.author","Lamersdorf, Annette"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Glueer, Claus"],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2022-12-01T08:31:03Z"],["dc.date.available","2022-12-01T08:31:03Z"],["dc.description.abstract","Introduction: Established scores estimate 10-year fracture risk in osteoporosis to assist with treatment recommendations. This study compares and contrasts the risk probabilities of major osteoporotic and hip fractures calculated by the FRAX tool with those of the DVO score, established in German-speaking countries.\nMaterial and methods: This seven-year retrospective study analyzes data of 125 male patients (mean age: 59.2±10.7 years) evaluated for osteoporosis. For the DVO score, the therapy threshold of >30% for vertebral and hip fractures suggested by DVO guidelines was implemented. We calculated fracture risks based on FRAX scores with aBMD and applied a common therapy threshold of ≥3% for hip fracture and subsequently determined the “DVO-equivalent risk level” for FRAX-based assessment that would identify as many male patients as identified by the DVO score. \nResults: Based on DVO score, 60.0% of patients had a 10-year risk of hip and vertebral fractures >30%. The recommendations for individuals based on FRAX scores for hip fracture with aBMD with risk ≥ 3% overlapped with those based on DVO score in 40.8% of patients. Patients identified for treatment only by DVO score presented a higher percentage of spine fractures (65% vs. 41%). The thresholds for this “DVO-equivalent risk level” for ‘FRAX with aBMD’ would be ≥ 6.9% for MOF and ≥ 2.1% for HF.\nThis study demonstrates that the DVO score was more sensitive than the FRAX score for patients with spinal fractures. We suggest considering the appropriate score and therapy threshold carefully in the daily care of male patients."],["dc.identifier.doi","10.1055/a-1977-4413"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1439-3646"],["dc.relation.issn","0947-7349"],["dc.title","Discrepancies between osteoporotic fracture evaluations in men based on German (DVO) osteoporosis guidelines or the FRAX score"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","331"],["dc.bibliographiccitation.issue","5-6"],["dc.bibliographiccitation.journal","Journal of Molecular Histology"],["dc.bibliographiccitation.lastpage","341"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Tezval, Hossein"],["dc.contributor.author","Dresing, Klaus"],["dc.contributor.author","Stuermer, Ewa Klara"],["dc.contributor.author","Blaschke, Martina"],["dc.contributor.author","Stuermer, Klaus Michael"],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2018-11-07T11:23:52Z"],["dc.date.available","2018-11-07T11:23:52Z"],["dc.date.issued","2009"],["dc.description.abstract","Urocortin-1 (UCN) a corticotropin releasing-factor (CRF) related peptide, has been found to be expressed in many different tissues like the central nervous system, the cardiovascular system, adipose tissue, and skeletal muscle. The effects of UCN are mediated via stimulation of CRF-receptors 1 and 2 (CRFR1 and 2, CRFR's) with a high affinity for CRFR2. It has been shown that the CRF-related peptides and CRFR's are involved in the regulation of stress-related endocrine, autonomic and behavioural responses. Using immunocytochemistry, immunohistochemistry and RT-PCR, we now can show the differentiation dependent expression of UCN mRNA and peptide in human mesenchymal progenitor cells (MSCs) directed to the osteoblastic phenotype for the first time. UCN expression was down regulated by TGF-beta and BMP-2 in the early proliferation phase of osteoblast development, whereas dexamethasone (dex) minimally induced UCN gene expression during matrix maturation after 24 h stimulation. Stimulation of MSCs for 28 days with ascorbate/beta-glycerophosphate (asc/bGp) induced UCN gene expression at day 14. This effect was prevented when using 1,25-vitamin D3 or dex in addition. There was no obvious correlation to osteocalcin (OCN) gene expression in these experiments. In MSCs from patients with metabolic bone disease (n = 9) UCN gene expression was significantly higher compared to MSCs from normal controls (n = 6). Human MSCs did not express any of the CRFR's during differentiation to osteoblasts. Our results indicate that UCN is produced during the development of MSCs to osteoblasts and differentially regulated during culture as well as by differentiation factors. The expression is maximal between proliferation and matrix maturation phase. However, UCN does not seem to act on the osteoblast itself as shown by the missing CRFR's. Our results suggest new perspectives on the role of urocortin in human skeletal tissue in health and disease."],["dc.identifier.doi","10.1007/s10735-009-9244-z"],["dc.identifier.isi","000275443300002"],["dc.identifier.pmid","19949969"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4160"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56279"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1567-2379"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Differentiation dependent expression of urocortin's mRNA and peptide in human osteoprogenitor cells: influence of BMP-2, TGF-beta-1 and dexamethasone"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","725"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cellular Biochemistry"],["dc.bibliographiccitation.lastpage","735"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Grundker, Carsten"],["dc.contributor.author","Blaschke, S."],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Emons, G."],["dc.contributor.author","Hofbauer, L. C."],["dc.date.accessioned","2018-11-07T10:33:20Z"],["dc.date.available","2018-11-07T10:33:20Z"],["dc.date.issued","2002"],["dc.description.abstract","The anti-resorptive effects of estrogen on bone metabolism are thought to be mediated through modulation of paracrine factors produced by osteoblastic lineage cells that act on osteoclastic lineage cells. Receptor activator of nuclear factor-kappaB ligand (RANKL) is the essential factor for osteoclast formation and activation and enhances bone resorption. By contrast, osteoprotegerin (OPG), which is produced by osteoblastic lineage cells acts as a decoy receptor that neutralizes RANKL and prevents bone loss. Recently, 17beta-estradiol was found to stimulate OPG mRNA levels and protein secretion in a human osteoblastic cell line through activation of the estrogen receptor (ER)-alpha. In this study, we assessed the effects of the phytoestrogen genistein on OPG mRNA steady state levels (by semiquantitative RT-PCIR and Northern analysis) and protein production (by ELISA) in primary human trabecular osteoblasts (hOB) obtained from healthy donors. Genistein increased OPG mRNA levels and protein secretion by hOB cells by up to two- to six-fold in a dose- (P< 0.0001) and time-dependent (P< 0.0001) fashion with a maximum effect at 10(-7) M. Co-treatment with the pure ER antagonist ICI 182,780 completely abrogated the stimulatory effects of genistein on OPG protein secretion, indicating that these effects were specific and directly mediated through the ER. Pre-treatment with genistein partially prevented the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production. The stimulation of OPG mRNA levels by genistein was not affected by the protein synthesis inhibitor, cycloheximide and was shown to be due to enhancement of OPG gene transcription. In conclusion, our data suggest that the phytoestrogen genistein is capable of upregulating the production of OPG by human osteoblasts. Thus, dietary sources of phytoestrogens may help to prevent bone resorption and bone loss by enhanced osteoblastic production of OPG. (C) 2002 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/jcb.10087"],["dc.identifier.isi","000173618800008"],["dc.identifier.pmid","11835398"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44583"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0730-2312"],["dc.title","Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","P1"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Journal of Endocrinology"],["dc.bibliographiccitation.lastpage","P19"],["dc.bibliographiccitation.volume","181"],["dc.contributor.author","Bollerslev, Jens"],["dc.contributor.author","Schalin-Jäntti, Camilla"],["dc.contributor.author","Rejnmark, Lars"],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Morreau, Hans"],["dc.contributor.author","Thakker, Rajesh"],["dc.contributor.author","Sitges-Serra, Antonio"],["dc.contributor.author","Cetani, Filomena"],["dc.contributor.author","Marcocci, Claudio"],["dc.contributor.author","Guistina, Andrea"],["dc.contributor.author","Van Hul, Wim"],["dc.contributor.author","Amrein, Karin"],["dc.contributor.author","Sikjaer, Tanja"],["dc.contributor.author","Hindie, Elif"],["dc.contributor.author","Vamvakidis, Kyriakos"],["dc.contributor.author","Corbetta, Sabrina"],["dc.contributor.author","Balaia, Zhanna"],["dc.contributor.author","Astor, Marianne"],["dc.contributor.author","Makay, Ozer"],["dc.contributor.author","Newey, Paul"],["dc.contributor.author","Hannan, Fadil"],["dc.contributor.author","Rolighed, Lars"],["dc.contributor.author","Appelman-Dijkstra, Natasha"],["dc.contributor.author","Wicke, Corrina"],["dc.contributor.author","Pilz, Stefan"],["dc.contributor.author","Saponaro, Federica"],["dc.contributor.author","Vestergard, Peter"],["dc.date.accessioned","2020-12-10T18:42:39Z"],["dc.date.available","2020-12-10T18:42:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1530/EJE-19-0316"],["dc.identifier.eissn","1479-683X"],["dc.identifier.issn","0804-4643"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16464"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78039"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Bone"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Schwetz, V."],["dc.contributor.author","Hacker, Nina"],["dc.contributor.author","Schnedl, C."],["dc.contributor.author","Amrein, K."],["dc.contributor.author","Lerchbaum, E."],["dc.contributor.author","Trummer, O."],["dc.contributor.author","Schweighofer, N."],["dc.contributor.author","Pieber, T."],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Obermayer-Pietsch, B."],["dc.date.accessioned","2018-11-07T09:10:37Z"],["dc.date.available","2018-11-07T09:10:37Z"],["dc.date.issued","2012"],["dc.format.extent","S105"],["dc.identifier.doi","10.1016/j.bone.2012.02.319"],["dc.identifier.isi","000304503500292"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26534"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","39th Annual Congress of the European-Calcified-Tissue-Society (ECTS)"],["dc.relation.eventlocation","Stockholm, SWEDEN"],["dc.relation.issn","8756-3282"],["dc.title","Determination of vitamin D deficiency by urine measurement"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]